---
title: Long Term Extension Study For SPM-005 Participants
nct_id: NCT01552538
overall_status: UNKNOWN
phase: PHASE1, PHASE2
sponsor: SetPoint Medical Corporation
study_type: INTERVENTIONAL
primary_condition: Rheumatoid Arthritis
countries: Bosnia and Herzegovina, Croatia, Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01552538.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01552538"
ct_last_update_post_date: 2016-11-01
last_seen_at: "2026-05-12T06:43:53.213Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Long Term Extension Study For SPM-005 Participants

**Official Title:** Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Rheumatoid Arthritis

**NCT ID:** [NCT01552538](https://clinicaltrials.gov/study/NCT01552538)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE1, PHASE2
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 18
- **Lead Sponsor:** SetPoint Medical Corporation
- **Conditions:** Rheumatoid Arthritis
- **Start Date:** 2012-01
- **Completion Date:** 2018-10
- **CT.gov Last Update:** 2016-11-01

## Brief Summary

This will be an open label multicenter study of the safety and efficacy of an active implantable vagal nerve stimulation (VNS) device in patients with rheumatoid arthritis. Patients who complete study SPM-005 will be enrolled in this study at the time of the last visit of the preceding study.

## Detailed Description

This will be an open label multicenter study of the safety and efficacy of an active implantable vagal nerve stimulation (VNS) device in patients with rheumatoid arthritis.

Patients who complete study SPM-005 will be enrolled in this study at the time of the last visit of the preceding study. The assessments at the last visit of the preceding study will also be used as baseline measures for the current study. If the patient has previously discontinued SPM-005 and greater than 30 days have elapsed since the final visit in SPM-005, baseline measures for the current study will be repeated, and an interim medical history will be taken to assess whether any new medical conditions were diagnosed in the time between studies.

Follow-up visits will occur at 3, 6, 12, 18, 24, 36 and 48 months. A final follow-up visit will occur for all remaining patients at study closure when the final enrolled subject has completed 48 months on study.

The study will continue until the last patient entered has completed 48 months in this study.

An Interim Visit or a phone contact must be performed a maximum of 2 months after any change in device settings. Interim visits may also be performed at any time at the investigator's discretion; either between scheduled visits, or after the patient has completed the Month 48 Visit, if the study is still ongoing.

The primary efficacy objective is to determine the long term efficacy of vagal nerve stimulation as assessed by the DAS28 score.

The secondary efficacy objectives are to determine the long term efficacy of vagal nerve stimulation as assessed by:

* the ACR 20, 50 and 70 response rate,
* the EULAR response rate, and
* changes in the Euro-QoL score.

The safety objectives are to determine the long term safely of vagal nerve stimulation as assessed by the subject incidence rates of:

* Adverse events
* Serious adverse events
* Device deficiencies

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 75 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients must have participated in study SPM-005

Exclusion Criteria:

* Inability to provide informed consent
* Significant psychiatric illness or substance abuse
```

## Arms

- **Cyberonics VNS System** (EXPERIMENTAL) — Continued stimulation w/Cyberonics VNS

## Interventions

- **Cyberonics VNS System** (DEVICE) — Stimulation with an active implantable electrical vagal nerve stimulation device

## Primary Outcomes

- **Change in rheumatoid arthritis Disease Activity Score (DAS) from baseline visit** _(time frame: 12-18 months)_

## Secondary Outcomes

- **Subject incidence of Adverse Events** _(time frame: 12-18 months)_

## Locations (4)

- Sveučilišna klinička bolnica Mostar, Mostar, Bosnia and Herzegovina
- Klinicki Centar Univerziteta, Reumatologija, Sarajevo, Bosnia and Herzegovina
- Sisters of Mercy Clinical Hospital Centre, Zagreb, Croatia
- Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sveučilišna klinička bolnica mostar|mostar||bosnia and herzegovina` — added _(2026-05-12)_
- `locations.klinicki centar univerziteta, reumatologija|sarajevo||bosnia and herzegovina` — added _(2026-05-12)_
- `locations.sisters of mercy clinical hospital centre|zagreb||croatia` — added _(2026-05-12)_
- `locations.academic medical center, university of amsterdam|amsterdam||netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01552538.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01552538*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*